“…Anti-IL-10 antibodies; TLR ligands and agonistic CD40 antibodies, anti-VEGF therapies, intratumoral injection of T. gondii; DC vaccines [24,30] Macrophages Anti-CCL2 antibodies; CSF1 and CSF1R antagonists; TLR ligand CpG and anti-IL-10 antibodies; IkK Kinase b inhibitors; HRG; FRb-targeted therapies; anti-CCL5 therapies; anti-CCL18 therapies; intravesicle installation of M. bovis; agonistic CD40 antibodies Anti-MARCO antibodies [39,44,49,[52][53][54][55][56][57][58][59] Pericytes VEGFR and PDGFR-b antagonists; VEGFR, PDGFR-b, and Tie-2 agonists; anti-RSG5 and anti-PD/PD-L1 therapies [61,68] Endothelial cells avb1, avb2, a5b1 integrin inhibitors; anti-VEGF and VEGFR agents [76,78] Fibroblasts Anti-CXCR-4 antibodies (SDF-1/CXCL12 inhibition); anti-VEGF-A antibodies and VEGF-R inhibitors; anti-PDGF-C/ PDGF-R inhibitors; MMP inhibitors; anti-IL6 antibodies; anti-HGF therapies; anti-FAP antibodies; Anti-TGFb and TGFbR inhibitors; anti-IL-11 therapies; anti-THSB1 therapies [80,86,90,[95][96][97][98] Neuronal cells NT3 and NT4 targeted therapies; GDNF inhibitors; anti-NGF antibodies; anti-PTN antibodies and N-syndecan inhibitors; BDNF inhibitors [99,105,109,111] Adipocytes Anti-IL-6 antibodies; anti-IL-8 antibodies; anti-CCL2 antibodies; anti-TIMP-1 antibodies; COX2 inhibitors, APN [119,120,122] APN, adiponectin; BDNF, brain-derived neurotrophic factor; CCL, chemokine ligand; CD, cluster of differentiation; COX, cyclooxygenase; CSF, colony stimulating factor; CSF1R, colony stimulating factor 1 receptor; CTLA, cytotoxic T-lymphocyteassociated protein; CXCL, C-X-C chemokine ligand; CXCR, C-X-C chemokine receptor; FAP, fibroblast activation protein; FRb, folate receptor beta; GDNF, glial cell line-derived neurotophic factor; HRG, histadine-rich glycoprotein; IL, interleukin; MMP, matrix metalloproteinase; NGF, n...…”